Biomolecule-based nanostructures are inherently multifunctional and harbour diverse
biological activities, which can be explored for cancer nanomedicine. The supramolecular …

Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

Effective drug delivery and prevention of postoperative recurrence are significant challenges
for current glioblastoma (GBM) treatment. Poor drug delivery is mainly due to the presence …

Nanomedicine-based anti-neuroinflammation strategy has become a promising dawn of
Parkinson's disease (PD) treatment. However, there are significant gaps in our …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Anthracyclines have been important and effective treatments against a number of cancers
since their discovery. However, their use in therapy has been complicated by severe side …

Malignant brain tumors, a heterogeneous group of primary and metastatic neoplasms in the
central nervous system (CNS), are notorious for their highly invasive and devastating …

Advanced treatments based on immune system manipulation, gene transcription and
regulation, specific organ and cell targeting, and/or photon energy conversion have …

Brain cancer, especially the most common type of glioblastoma, is highly invasive and
known as one of the most devastating and deadly neoplasms. Despite surgical and medical …

The blood–brain barrier (BBB), a unique structure in the central nervous system (CNS),
protects the brain from bloodborne pathogens by its excellent barrier properties …